'Very Impressive' Survival With Combo in First-Line Prostate Cancer Study

(MedPage Today) — SAN FRANCISCO — The first-line combination of olaparib (Lynparza) plus abiraterone (Zytiga) led to a significant overall survival (OS) advantage for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring…

Source link : https://www.medpagetoday.com/meetingcoverage/mgucs/120096

Author :

Publish date : 2026-02-27 22:43:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

‘Very Impressive’ Survival With Combo in First-Line Prostate Cancer Study

More Parents Say ‘No’ to Vitamin K Shots for Newborns

I woke up from an operation in agony and the pain never went away

Related Posts

Why illegal children’s homes are being paid up to £2m per child by councils

Atrial-Fixation TMVR Appears Feasible, Durable at 1 Year

Tool Predicts Difficult-to-Treat Depression, Even Before Drug Failure

Study Questions Methods Used in Alzheimer’s Drug Analysis

Pictorial Tool Helps Lupus Patients Stay on Hydroxychloroquine

Former CDC Chief Tom Frieden on the Latest Ebola Outbreak

Why illegal children’s homes are being paid up to £2m per child by councils

Atrial-Fixation TMVR Appears Feasible, Durable at 1 Year

Tool Predicts Difficult-to-Treat Depression, Even Before Drug Failure

Study Questions Methods Used in Alzheimer’s Drug Analysis

Pictorial Tool Helps Lupus Patients Stay on Hydroxychloroquine

Former CDC Chief Tom Frieden on the Latest Ebola Outbreak

No Infants Developed Measles After Utah Prophylaxis Regimen

From Missed Signals to Meaningful EoE Dialogue: The Impact of Shared Decision-making

Categories

Archives